Menu Search
Equities

Affluent Medical SAS

0JZ:BER

Affluent Medical SAS

Actions
  • Price (EUR)1.74
  • Today's Change-0.04 / -2.25%
  • Shares traded--
  • 1 Year change+37.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 17:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Affluent Medical SAS is a France-based company that manufactures surgical implants. It designs minimally invasive prostheses at mimicking human anatomy and restoring native physiology for critical functions in cardiovascular and urological therapies. It provides several products such as Kalios, Epygon, Artus. It helps in treating heart disease and urinary incontinence. The Company provides transcatheter and flow control technologies, such as mimicry of anatomy and restoration of physiology minimally invasive implant procedures, optimized and biocompatible components.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-17.04m
  • Incorporated2018
  • Employees66.00
  • Location
    Affluent Medical SAS320 avenue ArchimedeLes pleiades III Batiment BAIX-EN-PROVENCE 13100FranceFRA
  • Phone+33 442951220
  • Websitehttps://www.affluentmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.